Harmony Biosciences Holdings, Inc. (HRMY)
HRMY Stock Price Chart
Explore Harmony Biosciences Holdings, Inc. interactive price chart. Choose custom timeframes to analyze HRMY price movements and trends.
HRMY Company Profile
Discover essential business fundamentals and corporate details for Harmony Biosciences Holdings, Inc. (HRMY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Aug 2020
Employees
268.00
CEO
Jeffrey Dayno
Description
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
HRMY Financial Timeline
Browse a chronological timeline of Harmony Biosciences Holdings, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is $0.87, while revenue estimate is $242.13m.
Earnings released on 7 May 2026
EPS came in at $0.55 falling short of the estimated $0.76 by -27.63%, while revenue for the quarter reached $215.39m , missing expectations by -2.47%.
Earnings released on 24 Feb 2026
EPS came in at $0.38 falling short of the estimated $0.84 by -54.76%, while revenue for the quarter reached $243.78m , beating expectations by +1.44%.
Earnings released on 4 Nov 2025
EPS came in at $0.87 falling short of the estimated $0.92 by -5.43%, while revenue for the quarter reached $239.46m , missing expectations by -0.24%.
Earnings released on 5 Aug 2025
EPS came in at $0.68 falling short of the estimated $0.78 by -12.82%, while revenue for the quarter reached $200.49m , missing expectations by -8.94%.
Earnings released on 6 May 2025
EPS came in at $0.78 surpassing the estimated $0.59 by +32.20%, while revenue for the quarter reached $184.73m , missing expectations by -10.35%.
Earnings released on 25 Feb 2025
EPS came in at $0.85 surpassing the estimated $0.74 by +14.86%, while revenue for the quarter reached $201.27m , beating expectations by +9.86%.
Earnings released on 29 Oct 2024
EPS came in at $0.79 surpassing the estimated $0.67 by +17.91%, while revenue for the quarter reached $186.04m , missing expectations by -6.32%.
Earnings released on 6 Aug 2024
EPS came in at $0.20 surpassing the estimated -$0.06 by +433.33%, while revenue for the quarter reached $172.81m , missing expectations by -0.17%.
Earnings released on 30 Apr 2024
EPS came in at $0.67 surpassing the estimated $0.60 by +11.67%, while revenue for the quarter reached $154.62m , missing expectations by -0.04%.
Earnings released on 22 Feb 2024
EPS came in at $0.45 falling short of the estimated $0.48 by -6.25%, while revenue for the quarter reached $168.41m , missing expectations by -0.73%.
Earnings released on 31 Oct 2023
EPS came in at $0.75 surpassing the estimated $0.65 by +15.38%, while revenue for the quarter reached $160.27m , beating expectations by +7.65%.
Earnings released on 1 Aug 2023
EPS came in at $0.56 falling short of the estimated $0.63 by -11.11%, while revenue for the quarter reached $134.22m , missing expectations by -5.50%.
Earnings released on 2 May 2023
EPS came in at $0.48 surpassing the estimated $0.44 by +9.09%, while revenue for the quarter reached $119.13m , beating expectations by +2.53%.
Earnings released on 21 Feb 2023
EPS came in at $0.79 surpassing the estimated $0.58 by +36.21%, while revenue for the quarter reached $128.31m , beating expectations by +0.51%.
Earnings released on 1 Nov 2022
EPS came in at $0.95 surpassing the estimated $0.10 by +850.00%, while revenue for the quarter reached $117.21m , beating expectations by +3.19%.
Earnings released on 2 Aug 2022
EPS came in at $0.57 surpassing the estimated $0.40 by +42.50%, while revenue for the quarter reached $107.03m , beating expectations by +6.25%.
Earnings released on 3 May 2022
EPS came in at $0.51 surpassing the estimated $0.25 by +104.00%, while revenue for the quarter reached $85.31m , missing expectations by -3.66%.
Earnings released on 28 Feb 2022
EPS came in at $0.63 surpassing the estimated $0.32 by +96.88%, while revenue for the quarter reached $91.21m , beating expectations by +1.88%.
Earnings released on 9 Nov 2021
EPS came in at $0.51 surpassing the estimated $0.27 by +88.89%, while revenue for the quarter reached $80.73m , beating expectations by +2.36%.
Earnings released on 10 Aug 2021
EPS came in at $0.54 surpassing the estimated $0.19 by +184.21%, while revenue for the quarter reached $73.82m , beating expectations by +7.14%.
HRMY Stock Performance
Access detailed HRMY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
